Profile
Phillip P.
Gutry worked as a Director of Corporate Development at Gilead Sciences, Inc. from 2006 to 2011.
He then worked as a Principal at MPM BioImpact, Inc. from 2011 to 2015.
From 2015 to 2018, he was an Executive Director of Business Development at Regeneron Pharmaceuticals, Inc. He also served as a Director at Potenza Therapeutics, Inc. and Amphivena Therapeutics, Inc. Additionally, he was an Independent Director at Avalo Therapeutics, Inc. from 2015 to 2021.
From 2018 to 2020, he was the Chief Business Officer at Kronos Bio, Inc. and later served as the CFO, Chief Business & Accounting Officer at Graphite Bio, Inc. Mr. Gutry received his undergraduate degree from Dartmouth College and his MBA from The Wharton School of the University of Pennsylvania.
Former positions of Phillip Gutry
| Companies | Position | End |
|---|---|---|
| AVALO THERAPEUTICS, INC. | Director/Board Member | 2021-10-31 |
| KRONOS BIO, INC. | Corporate Officer/Principal | 2020-09-30 |
| REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2018-09-30 |
MPM BioImpact LLC
MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions. | Private Equity Investor | 2015-05-31 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 2011-04-30 |
Training of Phillip Gutry
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 12 |
|---|---|
Gilead Sciences, Inc.
Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops, manufactures and commercializes medicines for diseases | Health Technology |
Potenza Therapeutics, Inc.
Potenza Therapeutics, Inc. BiotechnologyHealth Technology Develops oncology programs and mechanisms for tumors detection | Health Technology |
MPM BioImpact LLC
MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions. | Finance |
Dartmouth College
Dartmouth College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Wilkerson Group
Wilkerson Group Medical/Nursing ServicesHealth Services Consulting services to pharmaceutical and medical products industry | Health Services |
Riverside Partners LLC
Riverside Partners LLC Investment ManagersFinance Riverside Partners invests in middle-market companies located in the United States primarily in North America with an EBITDA of USD 3 - 15 million. The firm focuses on technology and healthcare sectors. It participates in buyouts, recapitalizations, growth equity, divestitures, take private transactions and strategic add-on acquisitions. It makes control investments. | Finance |
Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics for patients with unmet clinical need in immunology and rare genetic diseases | Health Technology |
Amphivena Therapeutics, Inc.
Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Provides drug discovery services | Retail Trade |
The Wharton School of the University of Pennsylvania
The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kronos Bio, Inc.
Kronos Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel cancer therapeutics | Health Technology |
Graphite Bio, Inc.
Graphite Bio, Inc. BiotechnologyHealth Technology Operates as gene editing company for DNA integrations | Health Technology |
- Stock Market
- Insiders
- Phillip Gutry
















